Lilly hooks Hutchison for China cancer deal
This article was originally published in Scrip
Executive Summary
Lilly and Hutchison China MediTech's R&D company have signed a deal for the latter's VEGF receptor inhibitor fruquintinib, under which the US multinational will pay up to $86.5m plus tiered royalties starting in the mid-teens to its Chinese partner. The deal is the first time a big pharma company has licensed a Phase II oncology program in China specifically for the Chinese market.